| Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia CH Lin, CL Huang, YC Chang, PW Chen, CY Lin, GE Tsai, HY Lane Schizophrenia research 146 (1-3), 231-237, 2013 | 214 | 2013 |
| Glutamate signaling in the pathophysiology and therapy of schizophrenia CH Lin, HY Lane, GE Tsai Pharmacology Biochemistry and Behavior 100 (4), 665-677, 2012 | 168 | 2012 |
| Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial CH Lin, PK Chen, YC Chang, LJ Chuo, YS Chen, GE Tsai, HY Lane Biological psychiatry 75 (9), 678-685, 2014 | 123 | 2014 |
| Brain stimulation in Alzheimer's disease CH Chang, HY Lane, CH Lin Frontiers in psychiatry 9, 201, 2018 | 118 | 2018 |
| Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial CH Lin, CH Lin, YC Chang, YJ Huang, PW Chen, HT Yang, HY Lane Biological psychiatry 84 (6), 422-432, 2018 | 105 | 2018 |
| d-glutamate and Gut Microbiota in Alzheimer’s Disease CH Chang, CH Lin, HY Lane International journal of molecular sciences 21 (8), 2676, 2020 | 91 | 2020 |
| NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer's disease YJ Huang, CH Lin, HY Lane, G E Tsai Current neuropharmacology 10 (3), 272-285, 2012 | 87 | 2012 |
| New treatment strategies of depression: based on mechanisms related to neuroplasticity YJ Huang, HY Lane, CH Lin Neural plasticity 2017, 2017 | 76 | 2017 |
| Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging CH Lin, HT Yang, CC Chiu, HY Lane Scientific reports 7 (1), 14849, 2017 | 75 | 2017 |
| Machine learning and novel biomarkers for the diagnosis of Alzheimer’s disease CH Chang, CH Lin, HY Lane International journal of molecular sciences 22 (5), 2761, 2021 | 67 | 2021 |
| NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimer’s disease TG Lin CH, Huang YJ, Lin CJ, Lane HY Current Pharmaceutical Design 20 (32), 5169-5179, 2014 | 67 | 2014 |
| Decreased mRNA expression for the two subunits of system xc−, SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: Evidence in support of the hypo-glutamatergic … CH Lin, PP Lin, CY Lin, CH Lin, CH Huang, YJ Huang, HY Lane Journal of Psychiatric Research 72, 58-63, 2016 | 62 | 2016 |
| Novel therapeutic approaches for Alzheimer’s disease: An updated review TW Yu, HY Lane, CH Lin International journal of molecular sciences 22 (15), 8208, 2021 | 60 | 2021 |
| Precision psychiatry applications with pharmacogenomics: artificial intelligence and machine learning approaches E Lin, CH Lin, HY Lane International journal of molecular sciences 21 (3), 969, 2020 | 60 | 2020 |
| Early identification and intervention of schizophrenia: insight from hypotheses of glutamate dysfunction and oxidative stress CH Lin, HY Lane Frontiers in psychiatry 10, 93, 2019 | 60 | 2019 |
| Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital CH Lin, MC Chen, LS Chou, CH Lin, CC Chen, HY Lane Psychiatry research 180 (2-3), 74-79, 2010 | 58 | 2010 |
| Effects of antipsychotics on bone mineral density in patients with schizophrenia: gender differences CY Chen, HY Lane, CH Lin Clinical Psychopharmacology and Neuroscience 14 (3), 238, 2016 | 57 | 2016 |
| D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive impairment CH Lin, HT Yang, HY Lane Pharmacology Biochemistry and Behavior 185, 172760, 2019 | 51 | 2019 |
| Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer’s disease, and Parkinson’s disease WY Hsu, HY Lane, CH Lin Frontiers in psychiatry 9, 91, 2018 | 50 | 2018 |
| Relevant applications of generative adversarial networks in drug design and discovery: molecular de novo design, dimensionality reduction, and de novo peptide and protein design E Lin, CH Lin, HY Lane Molecules 25 (14), 3250, 2020 | 46 | 2020 |
